Pioneering technology firm TrakCel has appointed a new chief operating officer to direct its future growth.
James Rudolf joins the Cardiff-based company with 20 years experience in operations, sales and strategy across a range of technology businesses.
Mr Rudolf, who was previously COO of MooD International and before that MD of Target Group, will also take up the position of executive vice president of TrakCel.
The fast-growing company develops software for clinical trials that is designed to ensure the right patient gets the right therapy at the right time and location.
Mr Rudolf will be directing TrakCel’s operational growth strategies and global action implementation, focusing on continual improvement of services and support for the company’s growing list of cell and gene therapy customers.
“James brings a wealth of experience in delivering complex IT-based systems to the market.” said Keren Winmill, TrakCel’s chair and CEO. “We're excited to have James on board as TrakCel strives to bring its pioneering solutions to the global biotechnology community.”
Mr Rudolf said:
“I'm hugely excited about joining TrakCel at this time with a number of client projects being delivered and a very strong pipeline of future work. TrakCel is proving to be a valuable component in the cell therapy industry which itself is reaching a tipping point in terms of its advancements.
“TrakCel have a great team in place and I look forward to using my experience to deliver great success to our clients and to TrakCel.”
The appointment was assisted by Cardiff and London based executive search business Goodson Thomas.
Its MD Sian Goodson, said:
“James is among the top tier of executive talent in Wales with an impressive track record of understanding customers, taking products to market and facilitating growth. The combination of his commerciality, intellect and values convinced us from the outset that he was ideally positioned for a role of this kind.”
The appointment comes in the middle of an exciting period of growth for TrakCel. In December it announced plans to create 20 new jobs after receiving £125,000 business funding from the Welsh government, and last month it was awarded a £315,000 European investment to take part in a cell therapy project to help treat cancer.